Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis.
作者： CY Ahn , SK Bae , SH Bae , T Kim , YS Jung
DOI: 10.1111/J.1476-5381.2008.00105.X
关键词: Endocrinology 、 Western blot 、 Cirrhosis 、 Isozyme 、 Diabetes mellitus 、 Streptozotocin 、 Cytochrome P450 、 Medicine 、 Internal medicine 、 Oltipraz 、 Pharmacokinetics
摘要: Background and purpose: The incidence of diabetes mellitus is increased in patients with liver cirrhosis. Oltipraz currently trials to treat fibrosis cirrhosis induced by chronic hepatitis types B C primarily metabolized via hepatic cytochrome P450 isozymes CYP1A1/2, 2B1/2, 2C11, 2D1 3A1/2 rats. We have studied the influence on pharmacokinetics oltipraz expression hepatic, CYP1A, 2D 3A rats experimental cirrhosis. Experimental approach: was given intravenously (10 mg·kg−1) or orally (30 mg·kg−1) N-dimethylnitrosamine (LC rats) diabetes, streptozotocin (DM both (LCD control rats, pharmacokinetic variables measured. Protein measured using Western blot analysis. Key results: After i.v. p.o. administration LC DM AUC significantly greater smaller, respectively, than that In LCD (partially restored towards rats). Compared protein CYP1A increased, CYP2C11 decreased, but CYP2B1/2 not altered rats. Conclusions implications: cirrhosis, partially
sci-hub.se 参考文章(49)
Mark J. Ratain, Alfred Rademaker, Lisa Stucky-Marshall, M. Eileen Dolan, Olufunmilayo I. Olopade, Al B. Benson, Suzanne French, Sohrab Mobarhan, Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients. Clinical Cancer Research. ,vol. 6, pp. 3870- 3877 ,(2000)
MM Bradford, None, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Analytical Biochemistry. ,vol. 72, pp. 248- 254 ,(1976) , 10.1016/0003-2697(76)90527-3
Peter J. O’Dwyer, Christine Szarka, James M. Gallo, James M. Brennan, Paul B. Laub, Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose. Clinical Cancer Research. ,vol. 6, pp. 4692- 4696 ,(2000)
Choong Y. Ahn, Soo K. Bae, Young S. Jung, Inchul Lee, Young C. Kim, Myung G. Lee, Wan G. Shin, Pharmacokinetic Parameters of Chlorzoxazone and its Main Metabolite, 6-Hydroxychlorzoxazone, after Intravenous and Oral Administration of Chlorzoxazone to Liver Cirrhotic Rats with Diabetes Mellitus Drug Metabolism and Disposition. ,vol. 36, pp. 1233- 1241 ,(2008) , 10.1124/DMD.107.017442
Myung G. Lee, Win L. Chiou, Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism Journal of Pharmacokinetics and Biopharmaceutics. ,vol. 11, pp. 623- 640 ,(1983) , 10.1007/BF01059061
R FRYE, N ZGHEIB, G MATZKE, D CHAVESGNECCO, M RABINOVITZ, O SHAIKH, R BRANCH, Liver disease selectively modulates cytochrome P450--mediated metabolism. Clinical Pharmacology & Therapeutics. ,vol. 80, pp. 235- 245 ,(2006) , 10.1016/J.CLPT.2006.05.006
Haider Raza, Ijaz Ahmed, Annie John, Ashutosh K. Sharma, Modulation of xenobiotic metabolism and oxidative stress in chronic streptozotocin-induced diabetic rats fed with Momordica charantia fruit extract. Journal of Biochemical and Molecular Toxicology. ,vol. 14, pp. 131- 139 ,(2000) , 10.1002/(SICI)1099-0461(2000)14:3<131::AID-JBT2>3.0.CO;2-Q
Reem Elbekai, Hesham Korashy, Ayman El-Kadi, The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Current Drug Metabolism. ,vol. 5, pp. 157- 167 ,(2004) , 10.2174/1389200043489054
Joanna Z. Peng, Rory P. Remmel, Ronald J. Sawchuk, INHIBITION OF MURINE CYTOCHROME P4501A BY TACRINE: IN VITRO STUDIES Drug Metabolism and Disposition. ,vol. 32, pp. 805- 812 ,(2004) , 10.1124/DMD.32.8.805
M J Ratain, O I Olopade, F K Berezin, A B Benson, M E Dolan, R Mick, E Gupta, T M Baker, Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clinical Cancer Research. ,vol. 1, pp. 1133- 1138 ,(1995)